Hikma launches generic Vidaza

Hikma is introducing azacitidine for injection, in a dosage strength of 100 mg.

The product is the generic of Celgene’s Vidaza.

It is indicated for treatment of patients with the following French-American-British myelodysplastic syndrome subtypes: refractory anemia or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia.

Azacitidine for injection had a market value of approximately $82 million in the 12 months ending July 2020, according to IQVIA.